Dr. Brown is on Doximity
As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
450 Brookline Avenue
Dana-Farber Cancer Institute
Boston, MA 02215Phone(617) 632-4564
Fax(617) 582-7909- Is this information wrong?
Education & Training
Brigham and Women's HospitalResidency, Internal Medicine, 2017
Brigham and Women's HospitalFellowship, Hematology/Oncology, 2001 - 2004
Massachusetts General HospitalResidency, Internal Medicine, 1998 - 2001
Harvard Medical SchoolClass of 1998
Certifications & Licensure
MS State Medical License 2017 - 2021
MA State Medical License 2000 - 2022- American Board of Internal Medicine Hematology
Clinical Trials
- A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL Start of enrollment: 2014 Jun 01Barnes, J.,Brown, J.,Brown, J.R.,Arnason, J.E.
- Multi-center Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Start of enrollment: 2010 Aug 01James, D.F.,Jones, J.,Brown, J.,Rai, K.,Carpenter, M.,Kipps, T.J.
- Pyrimethamine for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Start of enrollment: 2010 Mar 01Brown, J.,Joyce, R.
- Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL) Start of enrollment: 2008 Feb 01James, D.F.,Mikler, E.,Gould, J.N.,Brown, J.R.,Rai, K.,Driscoll, N.,Smith, S.C.,Kipps, T.J.
- A Phase 1 Study of Obatoclax Mesylate (GX15-070MS) in Combination With Fludarabine and Rituximab in Previously Treated Patients With B-Cell Chronic Lymphocytic Leukemia (B-CLL) Start of enrollment: 2008 Jan 01Brown, J.R.
- A Phase I Dose Escalation Study of Lenalidomide (Revlimid) in Combination With Fludarabine-Rituximab (Rituxan) for Previously Untreated CLL/SLL Start of enrollment: 2007 Oct 01Brown, J.R.
- Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLL Start of enrollment: 2006 May 01Brown, J.R.
- Join now to see all
Publications & Presentations
PubMed
- Pneumocystis jirovecii pneumonia and institutional prophylaxis practices in CLL patients treated with BTK inhibitors.Ryan, C. E., Cheng, M. P., Issa, N. C., Brown, J. R., Davids, M. S.> ;Blood advances. 2020 Apr 14
- Acalabrutinib Monotherapy in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia: Updated Phase 2 ResultsJohn C. Byrd, William G. Wierda, Anna Schuh, Stephen Devereux, Jorge M. Chaves, Jennifer R. Brown, Peter Hillmen, Peter Martin, Farrukh T. Awan, Deborah M. Stephens, P...> ;Blood. 2020 Apr 9
- Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma.Reid W. Merryman, Natasha Catherine Edwin, Robert A. Redd, Jad Bsat, Matthew L Chase, Ann S. LaCasce, Arnold S. Freedman, Caron A. Jacobson, David C. Fisher, Samuel Ng...> ;Blood Advances. 2020 Mar 10
- Join now to see all
Abstracts/Posters
- Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 42-Month Follow-up of a Phase 2 StudyJennifer R. Brown, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- High Sensitivity NGS Analysis of MRD in CLL Patients Prospectively Treated with Ibrutinib Plus FCR (iFCR)Jennifer R Brown, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Final Results from the Multicenter, Open-Label, Phase II GIBB Study of Obinutuzumab+Bendamustine in Previously Untreated Patients with Chronic Lymphocytic LeukemiaJennifer R Brown, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- Cytogenetic and Molecular Marker Associations to Outcomes with Duvelisib and Ofatumumab Treatment in Patients with Relapsed or Refractory CLL/SLL in the DUO Trial61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- A Phase 3 Trial Comparing the Efficacy and Safety of Acalabrutinib in Combination with Venetoclax with or without Obinutuzumab, Compared with InvestigatorÍs Choice of ...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Outcomes of Ibrutinib (Ibr) Therapy in Ibr-Na¥ve Patients (pts) with Chronic Lymphocytic Leukemia (CLL) Progressing after Venetoclax (Ven)61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Join now to see all
Press Mentions
Clinical Challenges: Selecting First-Line Therapy in CLLMay 20th, 2019
Verastem Oncology Announces Fourth Quarter and Full-Year 2018 Financial Results and Corporate DevelopmentsMarch 12th, 2019- Verastem Oncology Outlines Strategic Priorities for 2019 and Highlights Recent ProgressJanuary 3rd, 2019
Hospital Affiliations
Brigham and Women's HospitalBoston, Massachusetts
Dana-Farber Cancer InstituteBoston, Massachusetts
Massachusetts General HospitalBoston, Massachusetts- North Shore Medical CenterSalem, Massachusetts
Boston Medical CenterBoston, Massachusetts
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
